In 2023, the composite success rate for clinical development in biopharma hit its highest level since 2018 thanks to the adoption of novel trial designs, predictive biomarkers, and digital methodologies, according to IQVIA. But waning R&D productivity is a significant industry concern. A substantial number of life science executives believe their organizations need to rethink…
Unlearn on shaving millions off clinical trial budgets with digital twins
Clinical trials are notoriously expensive, with Phase 3 studies costing upwards of around $55,000 per day and completed trials routinely costing in the tens of millions of dollars. The startup Unlearn aims to chip away at those costs using digital twin technology, a concept pioneered by NASA during the Apollo era to create ‘living models’…
AI in drug development: Janssen exploring potential of AI in everything from target discovery to clinical trials
As enterprise AI adoption surges, the life science industry stands at a pivotal juncture. “We are truly at a tipping point,” remarked Najat Khan, chief data science officer at Janssen, during the 2023 Stanford Drug Discovery Symposium. “It’s amazing how quickly we’ve been able to make progress across the whole value chain in terms of…